Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A1811 vs THP in HER2-Positive Early Breast Cancer
NCT07844291Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2031
01
Overview
Randomised, open-label trial of trastuzumab rezetecan in breast cancer (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Pathologic Complete Response at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07844291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844291.